Back to Search
Start Over
COVID-19 in Patients With Hematologic Malignancies: A Single Center Retrospective Study
- Source :
- Frontiers in Oncology, Vol 11 (2021), Frontiers in Oncology
- Publication Year :
- 2021
- Publisher :
- Frontiers Media S.A., 2021.
-
Abstract
- Initial studies that described the novel coronavirus (COVID-19) reported increased morbidity and mortality in patients with cancer. Of this group, patients with hematologic malignancies (HM) had the highest disease severity and death rates. Subsequent studies have attempted to better describe how COVID-19 affects patients with HM. However, these studies have yielded variable and often contradictory results. We present our single-institution experience with patients with HM who were diagnosed with COVID-19 from March 2020 to March 2021. We report 62 total cases with 10 patients who died during this time. The overall mortality was 16.1%. Mortality during the first two waves of COVID was 27.8% and 25%. Mortality during the third wave of COVID was 10%. The median age of patients was 67 years (range 20-89 years). 55% of patients had lymphoid malignancies and the majority had active disease at the time of diagnosis with COVID-19. 87% of patients had more than one co-morbidity. Important co-morbidities included cardiovascular disease and smoking history. 38.7% of patients had asymptomatic or mild disease, 54.8% required hospitalization, and 17.5% required ICU level care. In patients who required ICU level care, the mortality was 60%.
- Subjects :
- Cancer Research
medicine.medical_specialty
lymphoma
Disease
Single Center
Asymptomatic
Internal medicine
Medicine
Multiple myeloma
RC254-282
business.industry
Mortality rate
leukemia
Cancer
COVID-19
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Retrospective cohort study
Brief Research Report
medicine.disease
mortality
Lymphoma
multiple myeloma
Oncology
hematologic malignancy
medicine.symptom
business
Subjects
Details
- Language :
- English
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Frontiers in Oncology
- Accession number :
- edsair.doi.dedup.....70b7d68c46f3d708ad0ea12122e05c78